Eli Lilly and Company (LLY) financial statements and ratios from SEC XBRL: revenue $79.7B (TTM), net margin 31.7%, revenue growth 47.7% YoY, P/E 40.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $65.18B |
| Revenue (TTM) | $79.7B |
| Net Margin | 31.7% |
| Return on Equity | 78.8% |
| Debt / Equity | 1.62 |
| Current Ratio | 1.35 |
| Revenue Growth (YoY) | 47.7% |
| EPS Growth (YoY) | 26.2% |
| P/E Ratio | 40.0 |
| Price / Book | 31.57 |
| Price / Sales | 13.42 |
| Dividend Yield | 0.5% |
| Piotroski F-Score | 8/9 |
| Piotroski checks passed | 8 of 9 |
| Industry P/E (Pharmaceutical Products) | 15.0 |
| Sector P/E (Healthcare) | 20.7 |
LLY overview · LLY earnings · LLY KPIs · LLY documents · LLY ownership · LLY peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.